TY - JOUR
T1 - Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness
AU - Italian Melanoma Intergroup
AU - Ribero, Simone
AU - Galli, Francesca
AU - Osella-Abate, Simona
AU - Bertero, Luca
AU - Cattaneo, Laura
AU - Merelli, Barbara
AU - Tondini, Carlo
AU - Ghilardi, Laura
AU - De Giorgi, Vincenzo
AU - Occelli, Marcella
AU - Quaglino, Pietro
AU - Cassoni, Paola
AU - Palmieri, Giuseppe
AU - Massi, Daniela
AU - Mandala, Mario
AU - Queirolo, Paola
AU - Stanganelli, Ignazio
AU - Botti, Gerardo
AU - Caracò, Corrado
AU - Chiarion Sileni, Vanna
AU - Di Giacomo, Anna Maria
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: The impact of histologic regression on sentinel lymph node biopsy (SLNB) status and on clinical outcome is uncertain. Objective: To investigate whether and to what extent regression <75% is able to predict SLNB status and clinical outcome of patients with melanoma >1-mm thick. Methods: The study included patients with diagnoses given at 4 centers of the Italian Melanoma Intergroup. Univariate and multivariate Cox proportional hazard models stratified by center were used to analyze the effect of regression on disease-free interval and melanoma-specific survival. Results: Out of 1182 patients given primary cutaneous melanoma diagnoses during 1998-2015 with a Breslow thickness >1 mm, 954 (304 with and 650 without regression) were included in the analysis. The proportion of patients with a positive SLNB was lower in patients with regression than without (24.4% vs 31.6%, chi-squared test P =.0368). At multivariate analysis, no association was detected between regression and disease-free interval (hazard ratio 1.11, 95% confidence interval 0.85-1.46; P =.4509) or melanoma-specific survival (hazard ratio 1.05, 95% confidence interval 0.77-1.44; P =.7600). Limitation: Retrospective analysis. Conclusion: In our series, regression was not an independent prognostic factor in primary cutaneous melanoma patients with Breslow thickness >1 mm whereas it was associated with a lower incidence of SLNB positivity.
AB - Background: The impact of histologic regression on sentinel lymph node biopsy (SLNB) status and on clinical outcome is uncertain. Objective: To investigate whether and to what extent regression <75% is able to predict SLNB status and clinical outcome of patients with melanoma >1-mm thick. Methods: The study included patients with diagnoses given at 4 centers of the Italian Melanoma Intergroup. Univariate and multivariate Cox proportional hazard models stratified by center were used to analyze the effect of regression on disease-free interval and melanoma-specific survival. Results: Out of 1182 patients given primary cutaneous melanoma diagnoses during 1998-2015 with a Breslow thickness >1 mm, 954 (304 with and 650 without regression) were included in the analysis. The proportion of patients with a positive SLNB was lower in patients with regression than without (24.4% vs 31.6%, chi-squared test P =.0368). At multivariate analysis, no association was detected between regression and disease-free interval (hazard ratio 1.11, 95% confidence interval 0.85-1.46; P =.4509) or melanoma-specific survival (hazard ratio 1.05, 95% confidence interval 0.77-1.44; P =.7600). Limitation: Retrospective analysis. Conclusion: In our series, regression was not an independent prognostic factor in primary cutaneous melanoma patients with Breslow thickness >1 mm whereas it was associated with a lower incidence of SLNB positivity.
KW - cutaneous melanoma
KW - disease-free interval
KW - melanoma-specific survival
KW - outcome
KW - prognosis
KW - regression
KW - sentinel lymph node
UR - http://www.scopus.com/inward/record.url?scp=85056638227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056638227&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2018.06.054
DO - 10.1016/j.jaad.2018.06.054
M3 - Article
AN - SCOPUS:85056638227
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
ER -